Biofrontera Inc
NASDAQ:BFRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Wuxi Xuelang Environmental Technology Co Ltd
SZSE:300385
|
CN |
|
CMOC Group Ltd
SSE:603993
|
CN |
|
Coupang Inc
NYSE:CPNG
|
KR |
|
D
|
Dingzing Advanced Materials Inc
TWSE:6585
|
TW |
|
Bharat Gears Ltd
NSE:BHARATGEAR
|
IN |
|
Sterling Group Holdings Ltd
HKEX:1825
|
HK |
|
R
|
Rugvista Group AB (publ)
STO:RUG
|
SE |
|
L
|
Luxxu Group Ltd
HKEX:1327
|
HK |
|
SmartFinancial Inc
NYSE:SMBK
|
US |
|
C
|
Caina Technology Co Ltd
SZSE:301122
|
CN |
Biofrontera Inc
Long-Term Debt
Biofrontera Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biofrontera Inc
NASDAQ:BFRI
|
Long-Term Debt
$4.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Long-Term Debt
$39.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Long-Term Debt
$42.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
21%
|
|
|
Pfizer Inc
NYSE:PFE
|
Long-Term Debt
$61.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Long-Term Debt
$46.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Long-Term Debt
$40.9B
|
CAGR 3-Years
40%
|
CAGR 5-Years
20%
|
CAGR 10-Years
18%
|
|
Biofrontera Inc
Glance View
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
See Also
What is Biofrontera Inc's Long-Term Debt?
Long-Term Debt
4.6m
USD
Based on the financial report for Dec 31, 2025, Biofrontera Inc's Long-Term Debt amounts to 4.6m USD.
What is Biofrontera Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 1Y
12%
Over the last year, the Long-Term Debt growth was 12%.
